Recursion Pharmaceuticals, Inc.
RXRX
$3.05
-$0.10-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.07% | 26.92% | -32.98% | 30.14% | 29.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.07% | 26.92% | -32.98% | 30.14% | 29.32% |
| Cost of Revenue | 14.51% | 51.87% | 66.86% | 54.63% | 42.51% |
| Gross Profit | -15.06% | -56.75% | -91.64% | -59.09% | -44.88% |
| SG&A Expenses | -18.06% | 3.88% | 65.95% | 74.27% | 67.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.16% | 35.97% | 66.60% | 60.09% | 49.50% |
| Operating Income | -3.44% | -37.09% | -83.02% | -63.84% | -51.97% |
| Income Before Tax | 1.90% | -38.75% | -86.89% | -70.69% | -60.27% |
| Income Tax Expenses | -803.55% | 88.03% | 97.15% | 100.30% | 89.53% |
| Earnings from Continuing Operations | 2.61% | -39.06% | -89.42% | -73.14% | -62.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.61% | -39.06% | -89.42% | -73.14% | -62.31% |
| EBIT | -3.44% | -37.09% | -83.02% | -63.84% | -51.97% |
| EBITDA | 3.01% | -29.48% | -77.45% | -60.62% | -50.31% |
| EPS Basic | 32.35% | 10.74% | -17.10% | -8.88% | -9.78% |
| Normalized Basic EPS | 31.03% | 10.01% | -15.00% | -6.97% | -8.11% |
| EPS Diluted | 32.35% | 10.74% | -17.10% | -8.88% | -9.78% |
| Normalized Diluted EPS | 31.03% | 10.01% | -15.00% | -6.97% | -8.11% |
| Average Basic Shares Outstanding | 51.98% | 63.55% | 62.93% | 57.12% | 44.42% |
| Average Diluted Shares Outstanding | 51.98% | 63.55% | 62.93% | 57.12% | 44.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |